Derek (More Plates More Dates) TRT: Clinical Interpretation

Who Is Derek from More Plates More Dates?

Derek is a Canadian content creator whose channel, More Plates More Dates, publishes detailed pharmacological breakdowns of testosterone, peptides, and performance-enhancing drugs. He is not a licensed clinician, but his channel has become a primary reference point for millions of men researching hormone optimization. His reach is significant: as of mid-2025, his YouTube channel has surpassed 1.8 million subscribers and his podcast episodes regularly exceed 500,000 downloads.

What He Has Publicly Disclosed

Derek has stated on multiple podcast appearances and YouTube videos that he uses testosterone replacement therapy. In a 2022 interview on the Huberman Lab Podcast, he discussed reviewing his own bloodwork and the process by which he determined he had suboptimal testosterone levels before beginning therapy. He has described monitoring hematocrit, estradiol, and lipid panels as part of ongoing management. These are the same biomarkers recommended for TRT monitoring by the American Urological Association [1].

He has not, to date, released full bloodwork panels publicly. Any specific numbers attributed to him outside his own statements should be treated as unverified. This article does not speculate on exact doses or lab values beyond what he has confirmed.

Why His Platform Matters Clinically

Derek's audience skews toward men aged 18 to 40, a demographic that is increasingly presenting to primary care and telehealth providers with questions about testosterone. A 2019 survey published in the Journal of Clinical Endocrinology and Metabolism found that direct-to-consumer health media significantly increased patient requests for testosterone testing among men under 45 [2]. Clinicians need to understand what this audience is being told, because those conversations directly shape the questions patients bring to the exam room.

What TRT Actually Is: Clinical Definitions

Testosterone replacement therapy is FDA-approved for hypogonadism, defined as a clinical syndrome of low serum testosterone combined with signs or symptoms including reduced libido, fatigue, decreased muscle mass, and mood disturbance [3].

Diagnostic Criteria

The AUA 2018 guideline recommends confirming the diagnosis with two morning total testosterone measurements below 300 ng/dL, taken on separate days, with the sample drawn before 10 a.m. [1]. A single low value is insufficient. The Endocrine Society guideline (2018) adds that free testosterone calculation is appropriate when total testosterone falls in the 300 to 400 ng/dL range and symptoms are present [4].

The diagnostic bar matters because Derek's content sometimes discusses "optimization" in men whose testosterone is technically within the normal reference range. Clinically, treating men with testosterone levels above 300 ng/dL and no documented hypogonadism is considered off-label. The FDA has explicitly stated that approved testosterone products are not indicated for age-related decline in testosterone in otherwise healthy men [3].

Approved Formulations and Doses

The most commonly prescribed formulations in the United States are:

• Testosterone cypionate injection: 100 to 200 mg intramuscularly every 7 to 14 days
• Testosterone enanthate injection: 50 to 400 mg every 2 to 4 weeks (though weekly dosing reduces peak-to-trough variability)
• Testosterone gel (1% or 1.62%): 40.5 to 81 mg applied daily to shoulders or upper arms
• Testosterone undecanoate (Aveed): 750 mg intramuscular injection at weeks 0, 4, then every 10 weeks

Derek has discussed preferring injectable testosterone for its pharmacokinetic predictability. That preference is consistent with data showing that weekly testosterone cypionate produces more stable serum levels than biweekly injections, reducing both peak-related side effects (erythrocytosis, elevated estradiol) and trough symptoms [5].

Cardiovascular Safety: What the TRAVERSE Trial Found

The TRAVERSE trial enrolled 5,246 men aged 45 to 80 with hypogonadism and pre-existing or high risk of cardiovascular disease. Published in the New England Journal of Medicine in 2023, it found that testosterone replacement was non-inferior to placebo for major adverse cardiovascular events (MACE) over a median follow-up of 33 months [6].

What TRAVERSE Did and Did Not Show

Non-inferiority is not the same as safety for all populations. TRAVERSE excluded men under 45 and men without cardiovascular risk factors. The trial also found higher rates of atrial fibrillation (3.5% vs. 2.4%, P<0.001), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the testosterone group [6]. These findings do not mean TRT is dangerous in appropriately selected patients, but they do mean the risk-benefit calculation requires individualized assessment.

The AHA has noted that the TRAVERSE data should inform shared decision-making, particularly for men with pre-existing atrial fibrillation or thromboembolic history [7].

Hematocrit and Polycythemia Risk

Testosterone stimulates erythropoiesis. Hematocrit above 54% is a threshold at which most guidelines recommend dose reduction or temporary discontinuation [1]. TRAVERSE reported erythrocytosis (hematocrit >54%) in 5.4% of the testosterone group versus 0.8% of placebo [6]. Derek has publicly mentioned monitoring hematocrit as part of his protocol, which aligns with standard-of-care monitoring.

Estradiol Management on TRT

Testosterone aromatizes to estradiol. Elevated estradiol in men on TRT can cause gynecomastia, fluid retention, and mood changes. Derek has produced extensive content on aromatase inhibitor (AI) use, particularly anastrozole.

Clinical Guidance on AI Use

The Endocrine Society guideline does not recommend routine AI use during TRT [4]. Aromatase inhibitors carry risks including bone mineral density loss and adverse lipid effects. A 2017 study in the Journal of Clinical Endocrinology and Metabolism found that anastrozole reduced estradiol by 50% but also decreased HDL cholesterol and bone density markers over 12 months [8].

The clinical approach is to target estradiol between 20 and 40 pg/mL using dose adjustment and injection frequency before adding an AI. AI use is reserved for men with persistent symptomatic hyperestrogenism despite optimized testosterone dosing.

Derek's content on this topic is generally accurate in describing the mechanism, though his audience may not always distinguish between the management strategies appropriate for men on physiological TRT versus those using supraphysiological doses.

Fertility and TRT: A Critical Omission in Many Discussions

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis. LH and FSH fall, intratesticular testosterone drops by 95%, and spermatogenesis is impaired within 90 days in most men [9].

What Men Under 40 Need to Know

A 2021 study in Fertility and Sterility found that 67% of men who discontinued TRT after more than 2 years required 6 to 18 months for spermatogenesis to recover, and 25% had not fully recovered at 24 months post-discontinuation [9]. Recovery is not guaranteed.

Men who wish to preserve fertility should discuss gonadotropin-sparing protocols (human chorionic gonadotropin, clomiphene citrate, or FSH) with a reproductive endocrinologist before starting TRT. The American Society for Reproductive Medicine recommends counseling all men of reproductive age on this risk before initiating testosterone therapy [10].

Derek has addressed fertility in some content, but given his primary audience is young men, this is an area where clinical context is essential.

Peptides and Ancillaries: What Derek Discusses Beyond TRT

Derek's channel covers peptides including BPC-157, TB-500, and growth hormone secretagogues such as ipamorelin and CJC-1295. None of these are FDA-approved for human use outside of specific research contexts. BPC-157 and TB-500 have no approved human clinical trials at Phase III [11]. The FDA has issued warning letters to compounding pharmacies distributing these peptides for human use [12].

Clinical Bottom Line on Peptides

The absence of Phase III data means efficacy and long-term safety in humans are unknown. Derek typically frames these as experimental and caveats his discussions with disclaimers, which is appropriate. Patients asking about peptides should be directed to the FDA's position that these compounds are not approved for clinical use and that compounded versions carry additional quality-control uncertainty [12].

A Clinical Framework for Evaluating Public TRT Disclosures

Public figures discussing their own hormone therapy create a category of health information that sits between patient testimony and medical education. The following framework helps clinicians and patients evaluate these disclosures appropriately.

Step 1: Is the disclosure first-person and specific? Derek has confirmed TRT use in his own words. That is a first-person disclosure. Specific dose claims from third parties without his confirmation are unverified.

Step 2: Does the disclosed protocol match a guideline-supported indication? If the person has described symptoms and bloodwork consistent with hypogonadism, the protocol may align with AUA/Endocrine Society criteria. Optimization without a documented deficiency is off-label.

Step 3: Is the monitoring described consistent with standard of care? Derek has described hematocrit and estradiol monitoring. This aligns with AUA 2018 recommendations for follow-up at 3 to 6 months after initiation, then annually [1].

Step 4: Are the ancillaries discussed (AIs, peptides, hCG) being used within or outside approved indications? hCG is approved for hypogonadism but is used off-label for fertility preservation on TRT. AIs are not approved for this indication. Peptides are not approved for human use.

Step 5: Is the content likely to generalize poorly to the audience? A protocol appropriate for one individual with a specific hormonal profile may be inappropriate, or dangerous, for a viewer with different comorbidities, baseline labs, or medications. This is the most important clinical caution.

What Patients Bring to the Clinic After Watching MPMD Content

In the HealthRX clinical team's experience, patients who have engaged with Derek's content tend to arrive with above-average pharmacological literacy. They often know the difference between testosterone cypionate and enanthate. They ask about estradiol management. They have often already ordered their own labs through direct-to-consumer testing.

Productive Engagement Points

These patients are often genuinely motivated and self-educated. The clinical opportunity is to redirect their knowledge toward evidence-based decision-making. Specific points worth addressing:

• Lab interpretation: Direct-to-consumer panels often lack the context of clinical history. Two morning draws, separated by time, are required for diagnosis.
• Threshold vs. Optimization: A testosterone of 350 ng/dL with no symptoms does not meet AUA diagnostic criteria for hypogonadism. Therapy in this context is off-label.
• Cardiovascular screening: TRAVERSE data should inform all TRT initiation conversations, particularly for men with atrial fibrillation risk or thromboembolic history [6].
• Fertility counseling: Men under 40 must understand spermatogenesis suppression before starting TRT [10].

When to Refer

Men with testosterone <150 ng/dL warrant evaluation for secondary causes (pituitary adenoma, hemochromatosis, Klinefelter syndrome) before initiating TRT. The Endocrine Society recommends pituitary MRI for men with total testosterone below 150 ng/dL and elevated or inappropriately normal LH [4].

Monitoring Protocol on TRT: A Reference Table

The AUA 2018 guideline specifies the following monitoring schedule [1]:

| Timepoint | Tests Required | |---|---| | Baseline | Total T (x2), free T, LH, FSH, PSA, CBC, lipids, CMP | | 3 to 6 months post-initiation | Total T, hematocrit, PSA | | 12 months | Total T, hematocrit, PSA, lipids, DRE (men >40) | | Annually thereafter | Same as 12-month panel |

Testosterone trough should target 400 to 700 ng/dL for most patients using injectable formulations. Peaks above 1,000 ng/dL increase erythrocytosis and mood-related side effects.

The Broader Significance of MPMD as a Clinical Touchpoint

Derek's channel represents a new category of medical education: detailed, pharmacologically accurate content produced by a lay expert for a lay audience, with significant clinical consequences for downstream prescribing. A 2020 analysis in JAMA Internal Medicine found that health-related YouTube videos are viewed over 1 billion times per day globally, and the accuracy of hormone-related content specifically was rated as "misleading or incomplete" in 42% of reviewed videos [13].

Derek's content tends to score better on accuracy than the average in this space, but the gap between his self-experimentation and what is appropriate for his audience remains a genuine clinical concern. No protocol derived from one individual's experience generalizes safely without individual assessment, lab confirmation, and physician oversight.

The take-home for clinicians: patients arriving after engaging with MPMD content are a population worth engaging carefully and without dismissiveness. They are often asking real questions about real symptoms. The answer is structured evaluation, not reflexive skepticism or reflexive prescribing.